Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

However, due to the limited sample size, we did not observe a clear trend between the efficacy and survival data in these subgroups (Figure S2 ).

also in 19,460 other papers